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Bone disease in predialysis, hemodialysis, and CAPD patients: Evi-
dence of a better bone response to PTH. The spectrum of bone disease in
predialysis and dialysis patients has changed during the last decade. The
incidence of aplastic bone disease has increased and this can not be
attributed to bone aluminum deposition; moreover, low bone cellular
activity is present despite a moderate elevation in PTH levels. This study
compares PTH levels and types of bone disease in both predialysis and
dialysis patients from the same geographical area. We prospectively
studied 119 unselected end-stage renal disease patients: 38 were immedi-
ately predialysis (PreD), 49 on hemodialysis HD), and 32 on CAPD. A
bone biopsy was performed in all patients. Aplastic bone disease with
< 5% bone surface aluminum was a common finding (48%, 32%, and
48%, in PreD, HD, and CAPD, respectively). In all groups, an intact PTH
level below 120 pg/mI was highly predictive of low bone turnover.
Conversely, a PTH level above 450 pg/ml was always associated with
histologic features of hyperparathyroid bone disease. Among the bone
histomorphometric parameters, osteoblast surface showed the best corre-
lation with intact PTH in each group, and the slope of the regression line
for this correlation was significantly steeper in HD and CAPD than PreD
patients. Thus, the range of PTH (95% confidence limit bands) needed to
obtain a normal osteoblast surface of 1.5% was greater in preD than in
HD and CAPD patients (300 to 500 vs. 75 to 260 pglml, respectively). In
all groups some degree of marrow fibrosis was observed when PTH levels
were greater than 250 pg/mI. Thus, PTH levels of 120 to 250 pg/mI (2 to
4 times the upper normal limit) were required to avoid low bone turnover
and hyperparathyroid bone disease in patients receiving maintenance
dialysis. By contrast, in preD patients, a PTH range of 300 to 500 pg/mI
was required to maintain a normal osteoblast surface; however, this range
of PTH levels was also associated with a mild degree of marrow fibrosis.
If mild marrow fibrosis (< 0.5%) was admitted, the corresponding PTH
range was 300 to 375 pg/mI. In conclusion, aplastic bone disease without
significant bone surface aluminum was a common finding in our predialy-
sis, hemodialysis, and CAPD patients. Maintenance dialysis improved the
bone response to PTH. Finally, the results of our study help define a range
of intact PTH levels that would be desirable in order to avoid both aplastic
bone disease and significant hyperparathyroid bone disease.
The spectrum of bone disease in dialysis patients has been
reported to have changed during the last decade [1—4]. In a series
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of recent reports of dialysis patients from Toronto, Canada, low
bone turnover (osteomalacia and aplastic lesion) was observed in
66% of CAPD patients and 39% of hemodialysis patients [1—31.
However, in these studies, approximately one-third of the 259
dialysis patients (CAPD and hemodialysis) had levels of stainable
bone surface aluminum greater than 25% [1]. In another study of
30 patients with end-stage renal disease evaluated immediately
before the initiation of dialysis, 34% of patients had low bone
turnover, 27% aplastic lesion and 7% osteomalacia [5]. In this
study, significant bone aluminum staining was only detected in two
patients. Results from these reports suggest that the incidence of
low bone turnover, especially the aplastic lesion, has increased
during the past decade, although in the Toronto study it is difficult
to eliminate aluminum as a contributing factor. Furthermore, the
results cited above serve to emphasize that a study contrasting the
types of bone disease in the predialysis and dialysis population has
not been performed in a single geographic area.
When compared to dialysis patients with high bc ne turnover
(osteitis fibrosa or mixed disease), patients with low bone turnover
have relatively low intact PTH levels [1, 3—7]. An evaluation of the
relationship between intact PTH levels and bone histology has
been performed in two studies with dialysis patients [7, 81 and in
a single study of the predialysis population [5]. In the study by
Quarles, Lobaugh and Murphy [81, dialysis patients with low bone
turnover were excluded in order to eliminate confounding vari-
ables such as aluminum which could interfere with the biological
effect of PTH on bone. In the other study in dialysis patients by
Cohen Solal et al [71, the correlation between PTH and bone
histologic parameters was considerably lower than that reported
by Quarles et al [8]. While it could be argued that the study by
Quarles et al [8] had a disproportionate number of patients with
marked hyperparathyroidism, the study by Cohen Solal et a! [7]
appeared to have a disproportionate representation of patients
with mild hyperparathyroidism and bone activity.
To date, no study has determined the distribution of renal
osteodystrophy in both predialysis and dialysis populations simul-
taneously. By evaluating whether the bone response to PTH is
different between the predialysis and dialysis population, it should
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be possible to learn whether maintenance dialysis affects the bone
response to PTH.
The purpose of the present study was: (1) to ascertain the
distribution of the types of renal osteodystrophy in both the
predialysis and dialysis population in a single geographic area; (2)
to determine the correlation between PTH and bone histology in
both high and low turnover bone disease in predialysis and dialysis
patients; (3) to evaluate whether dialysis improves the bone
response to PTH; and (4) to determine whether differences in
bone histology and the bone response to PTH are present
between CAPD and hemodialysis patients. To accomplish these
goals, 38 patients with end-stage renal disease in whom dialysis
would be required within a short period of time and 81 patients on
maintenance dialysis were studied.
Methods
This prospective cross-sectional study was performed in two
hospitals, one in Tenerife and the other in Gran Canaria; both are
located in the Canary Islands. From October 1988 to January
1991, every patient evaluated for maintenance dialysis therapy or
receiving maintenance dialysis for more than eight months
(CAPD or hemodialysis) was asked to participate in the study.
Eighty percent (119 of 149) of the patients agreed to participate in
the study and underwent a bone biopsy.
Thirty-eight of the 119 patients were immediately predialysis,
had creatinine clearances < 10 ml/min/1.73 m2, and required
maintenance dialysis within two months after entering the study.
The other 81 patients had received maintenance dialysis for more
than eight months and included 49 hemodialysis and 32 CAPD
patients. For both hemodialysis and CAPD, the dialysate calcium
concentration was 7 mg/dl. The aluminum concentration in the
dialysis fluid was measured at regular intervals and was consis-
tently below 10 tgIliter.
Calcium carbonate was used as the primary phosphate binder.
Aluminum hydroxide was added to the regimen only if either
calcium carbonate resulted in intolerance or did not adequately
control the serum phosphorus (> 5.5 mgldl). At the time of the
bone biopsy, 15 (40%) predialysis and 56 (70%) dialysis patients
were receiving moderate amounts of aluminum hydroxide (< 1.8
glday). The cumulative dose of aluminum hydroxide administered
to each patient was calculated from their records. Six hemodialysis
and 12 CAPD patients had received oral la-OHD3 (0.5 jig/day)
during the six months preceding the bone biopsy. None of the
predialysis patients had received any form of vitamin D therapy.
No patient had previous parathyroidectomy, was anephric, or was
receiving steroid or anticonvulsant therapy.
Bone biopsy
Bone biopsies were performed using a standard technique
described in our previous studies [9, 10]. Briefly, a transiliac bone
biopsy specimen was obtained with a 7 mm Bordier trephine after
in vivo double tetracycline labeling which was separated by an
interval of ten days. Five days after the second course of deme-
clocycline, the bone specimen was obtained. In 15 hemodialysis
and 3 CAPD patients, the bone biopsy was obtained at the time of
cadaveric renal transplantation. Thus, in vivo tetracycline labeling
could not be performed. Undecalcified sections of trabecular
bone were stained by the Masson-Goldner method [9, 10] and the
histologic stain for aluminum was performed with the aurintricar-
boxylic acid method [11]. Quantitative measurements were made
for the following histological parameters: total bone volume
(BV/TV%), osteoid volume (OV/BV%), volume of fibrosis
(Fb.V/TV%), osteoid seam thickness (0 Th, jim), osteoid surface
(OS/BS%), total surface stained with aluminum (AIIBS%), osteo-
blast surface (Ob.S/BS%), and osteoclast number per mm2 tissue
section (N,OcITA; mm2). The dynamic parameters of bone for-
mation included: mineral appositional rate (MAR expressed in
jim/day) and bone formation rate (BFR/BS expressed in tim3!
jim2/day) obtained by multiplying the MAR by the total labeled
mineralizing surface (double-labeled plus one half of the single-
labeled surface). Bone biopsies were classified by the method of
Sherrard et al [1, 12, 13]. For the diagnosis of osteomalacia,
OV/BV was> 15% and Fb.V/TV was < 0.5%; for the diagnosis
of aplastic lesion OV/BV was < 15% and Fb.VJTV <0.5%. Both
osteomalacia and the aplastic lesion were associated with a
BFR/BS <0.031 jim3/jim2/day, which is the lowest reported value
in normal individuals [7, 141. For the diagnosis of mild osteodys-
trophy, OV/BV was < 15%, Fb,V/TV < 0.5%, and BFR/BS>
0.03 1 jim3/p.m2/day. For the diagnosis of osteitis fibrosa, OV/BV
was < 15%, Fb.V/TV > 0.5%, and BFR/BS > 0.031 p,m3/p.m21
day; and for the diagnosis of mixed disease OV/BV was > 15%,
Fb.V/TV > 0.5%, and the BFR/BS was variable. The 18 dialysis
patients without previous in vivo tetracycline labeling were not
included in the above-mentioned classification, although their
static bone parameters were used in the correlation study with
PTH levels. Bone biopsies from 18 normal individuals residing in
Tenerife and who were cadaveric kidney donors provided normal
values of static bone parameters.
Biochemical parameters
Blood samples for the determination of biochemical parame-
ters were obtained after an overnight fast during the same week in
which the bone biopsy was performed. In hemodialysis patients,
blood was obtained before the dialysis session. In the 18 patients
from whom the biopsy was performed during the anesthesia for
kidney transplantation, blood was obtained before the dialysis
session in preparation for surgery. Calcium, phosphorus and
alkaline phosphatase were measured by standard automated
techniques. Bicarbonate levels were measured anaerobically using
a blood gas analyzer (ABL, Radiometer, Copenhagen, Denmark).
Intact PTH was measured by immunoradiometric assay (Allegro,
Nichols Institute, San Juan Capistrano, CA, USA); the normal
range for this assay is 10 to 65 pg/mI. Intra- and interassay
coefficients of variation were 5.7 and 14.9%, respectively. Serum
aluminum levels were measured by graphite furnace atomic
absorption [10].
Statistical analysis
Linear regression analysis was used to correlate PTH levels with
bone histologic parameters. In order to measure the linear
association between two variables while adjusting for the linear
effects of additional variables, partial correlation analysis was
used. Comparison of mean regression line slopes between several
groups was done by means of covariance analysis [15]. Post-hoc
comparisons were done by the use of dummy variables [16]. The
predictive value of PTH concentration for the diagnosis of the
bone histological lesion is expressed in terms of sensitivity,
specificity and positive predictive value [17]. Chi-square or Fish-
er's test were used to compare two independent proportions.
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Table 1. Patient characteristics and laboratory parameters
Predialysis(N = 38)
Hemodialysis
(N = 49)
CAPD
(N = 32)
All dialyses
(N 81)
Age years 47 16 45 16 48 12 46 14
Sex (M/F) 23/15 35/14 22/10 57/24
Diabetics % 13 10 21 15
Dialysis duration — 41 38 15 4" 28 32
months
Cumulative
Al (OH), 0.87 1.40 4.55 4.5" 2.59 1.05' 3.54 3.36"
dose kg
Sca mg/di 8.11 0.82 9.31 0.83" 9.54 0.60a 9.42 0.73"
SPO4 mg/dl 6.37 1.37 6.06 1.46 4.61 1.07" 5.33 j47a
HCO, mEq/L 20.7 3.2 21.3 2.8 21.8 1.9 21.6 2.4
ALP lU/liter 238 109 454 869 260 240 397 616.04
Intact PTH 421 413 437 474 273 315 361 414
pg/mi
Data are expressed as mean Sn.
Normal values are: 9 to 10.5 mg/dl; S4 3 to 4.5 mg/dl; CO,H 23
to 30 mEq/liter; ALP 80 to 260 lU/liter; PTH 10 to 65 pg/mI.
P < 0.01 vs. predialysis
"P < 0.001 vs. predialysis
P < 0.05 vs. predialysis
"P < 0.01 vs. hemodialysis
Comparison between parameters from two different groups were
performed using the unpaired t-test. One way analysis of variance
followed by Newman-Keuls test was used to assess differences
between more than two means. Tests were performed using the
SPSS for Windows® computer program [181. Data are expressed
as the mean SD.
Results
Patient characteristics are shown in Table 1. The cumulative
dose of Al(OH)3 was lower in predialysis patients. The serum
calcium concentration was lower in predialysis than CAPD and
hemodialysis patients (P < 0.01); the serum phosphorus concen-
tration was higher in predialysis than CAPD patients (P < 0.01),
but was not different than hemodialysis patients. The duration of
dialysis was shorter in CAPD than hemodialysis patients and
serum phosphorus was lower in CAPD than hemodialysis patients
(P < 0.01). The serum levels of PTH and alkaline phosphatase,
although lower in CAPD than hemodialysis patients, were not
significantly different.
Bone histomorphometric parameters of all patients groups
combined are shown in Table 2. Although statistical analysis was
performed, the differences were primarily due to the definitions of
the different types of renal bone disease. The incidence of the
different types of bone disease in predialysis, hemodialysis and
CAPD patients is shown in Figure 1. Aplastic bone disease was a
common finding in both predialysis and dialysis patients, although
it was more common in CAPD than hemodialysis patients.
Conversely, osteitis fibrosa tended to be more frequent in hemo-
dialysis than CAPD patients (14% vs. 32%, P = 0.07). The
trabecular bone surface stained with aluminum was less than 10%
in all except four patients; these included a predialysis patient with
osteomalacia, two hemodialysis patients, one with osteomalacia
and the other with osteitis fibrosa, and a CAPD patient with
osteomalacia.
Comparison of intact PTH levels with bone
histomoiphometric parameters
The correlation coefficients between PTH and histomorphor-
metric parameters in the different groups of patients are shown in
Table 3. In all groups, significant correlations were observed
between PTH and both static and dynamic bone indices, The
correlation coefficient was highest for the osteoblast surface
followed by fibrosis volume and osteoclast number/mm2. After
controlling for the effect of the other variables, the partial
correlation coefficient was still highest for the osteoblast surface in
all groups. However, when only patients with intact PTH levels
below 200 pg/mI (3 X the upper limit of normal) were considered,
the correlations between PTH and bone parameters were no
longer significant (Table 4). Conversely, the correlations were
maintained in those patients with intact PTH levels > 200 pg/ml
(Table 4). A similar finding was observed if the patients were
separated in low and high bone turnover,
Plasma concentration of intact PTH levels and prediction of the
bone histological lesion
PTH levels were significantly higher in patients with osteitis
fibrosa and mixed disease than in the other histologic forms of
bone disease (Fig. 2). In Table 5, the type of bone disease as
predicted from the PTH level is shown. A PTH level below 120
pg/ml was highly predictive of low turnover bone disease (osteo-
malacia or aplastic bone disease) especially in dialysis patients.
Conversely, a PTH level greater than 450 pg/mI was 100% specific
for the diagnosis of hyperparathyroid bone disease (mild, osteitis
fibrosa or mixed disease); 23 of 26 patients with PTH levels
greater than 450 pg/mI had advanced hyperparathyroid bone
disease (osteitis fibrosa or mixed disease). None of the patients
with low bone turnover had a PTH level > 450 pg/ml.
Plasma level of intact PTH which is associated with an "optimal"
bone histology
A significant correlation was observed between PTH and the
osteoblast surface in both predialysis and dialysis patients (Table
3). While the correlation coefficient was similar in both groups,
the slope of the regression line, as shown in Figure 3, was lower in
predialysis than in hemodialysis (0.005 vs. 0.01, P < 0.001) or
CAPD patients (0.005 vs. 0.009; P < 0.01). Hemodialysis and
CAPD patients showed a similar slope (P = 0.66). In the normal
individual with expected PTH levels between 10 and 65 pglml, the
mean osteoblast surface was 1.5%. In predialysis patients, a 1.5%
osteoblast surface was associated with a PTH concentration
between 300 and 500 pg/mI (95% confidence limit) (Fig. 3). In
chronic dialysis patients, a 1.5% osteoblast surface was associated
with a PTH concentration between 75 and 260 pg/mI (95%
confidence level).
As shown in Figure 4, the slope of the mean regression line
between PTH and marrow fibrosis was steeper in hemodialysis
than predialysis patients (P < 0.001). Similar findings were
observed when the comparison was between PTH and osteoclast
number (P = 0.001) and PTH and bone formation rate (P < 0.05).
Patients on CAPD showed similar slopes as predialysis patients,
which were significantly less steep than in hemodialysis patients
(Fig. 4). However, when matching for time on dialysis and
including in the analysis only those hemodialysis patients being
dialyzed for less than 18 months (12 6 months compared with
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Table 2. Histomorphometric parameters in the different histological bone lesions
BVITV OV/BV
0Th pm
OS/BS Ob.S/BS N.Oc/T.A.
mm2
Fb.V1T'V
%
MAR
pm/day
BFR/BS
pm3/pm2/day A1/BS %%%
Mild 23.1 4.9 10.2 3•1h 26ah 54•7 22.4 0.8 0.4 0.3" 0.4 02ag 1.6 06abC 0.2 0.2"" 0.2 0.7"
(N = 13)
Osteitis 29 10.2° 11 3" 13.6 2.9"" 66.7 17" 5 4.3 1.9 2.5 2.7 5 1.7 1""" 0.3 04bc 0.9 25b
fibrosa
(N = 27)
Mixed 29292d 22.6±7.9"" 22.6±7 71.7±18" 6.4±7.5 2.2±2.3 4.8±5.2 0.6±0.9 0.14±0.3 11÷3b
(N= 11)
Aplastic 21.4 6.3 8.3 34ab 8.9 2.2"" 45 27.8 0.4 0.5"" 0.3 0.4" 0.3 02ag 0.2 0.4 0.007 0.04 0.4 1.5"(N = 42)
Osteomalacia 24 4 19.2 3 18 2.4 77.2 17.1" 0.7 0.6"" 0.4 0.4"' 0.3 03fg 0.16 0.4 0.01 0.04 12.5 17.7
(N =8)
Normal 23.2 3.9 1.9 1 8.7 2.5 10.2 5.7 1.5 0.8 0.15 0.2 0 0.6 0.2" 0.08 0.03" 0
(N = 18)
"P < 0.01 vs. mixed
"P < 0.01 vs. osteomalacia
P < 0.01 vs. aplastic
dp < 0.05 vs. aplastic
p < 0.01 vs. osteitis fibrosa
fp < 0.05 vs. mixed
g P < 0.05 vs. osteitis fibrosa
From reference 14
Table 3. Linear correlation coefficients between intact PTH and
selected histomorphometric measurements in the different groups of
patients
Predialysis(N = 38)
Hemodialysis(N = 49)
CAPD
(N = 32)
All dialysis(N = 81)
BVITV % 044" 0.488 053b 0.42"
Ob.S/BS % 0.86" 0.818 0.8Y' 0.818
N.Oc/TA mm2 0.68" 0.74" 0.628 0.70a
Fb.V/TV % 0.74a 0.748 0.658 0.68'
MAR pm/day 0.37" Q47C 0.628 0.44a
BFRJBS J.un3/ 043b 0.648 052" 0.578
pm2lday
"p < 0.001; "P < 0.01; "P < 0.05
Fig. 1. Distribution of bone disease in the 38 predialysis (s), 34 hemodial-
ysis (), and 29 CAPD patients (U). Abbreviations are: ABD, aplastic;
OM, osteomalacia; MHP, mild hyperparathyroidism; OF, osteitis fibrosa;
Mixed, mixed lesions.
15 4 months in CAPD patients), the slopes of the mean
regression lines were no longer different between hemodialysis
and CAPD patients (marrow fibrosis 0.002 vs. 0.003; osteoclast
number 0.0001 vs. 0.0001; bone formation rate 0.0002 vs. 0.0003,
respectively).
Although the slope of the regression line between PTH and
bone fibrosis was steeper in hemodialysis than in predialysis or
CAPD patients, bone fibrosis was observed only when PTH levels
were greater than 250 pg/mi in all the groups, values which
correspond to the X-axis intercept of the inferior 95% confidence
limit band (Fig. 4).
Discussion
The present study provides a current evaluation of the distri-
bution of the types of renal osteodystrophy from a single geo-
graphic area in both maintenance dialysis patients and predialysis
patients with advanced azotemia. Moreover, this study provides a
correlation between intact PTH levels and parameters of bone
Table 4. Linear correlation coefficients between intact PTH and
selected histomorphometric measurements in the different groups of
patients as a function of the PTH levels
Predialysis All dialyses
PTH <200 PTH> 200 PTH < 200 PTH > 200
pg/mi pg/mi pg/mi pg/mi(N = 14) (N = 24) (N = 43) (N = 38)
BV/TV % 0.14 0.35 0.12 0.39°
Ob.S/BS % 0.29 0.818 0.25 0.74"
N.Oc/TA mm2 0.14 0.61" 0.10 0.66"
Fb.V/TV % 0.25 0.56" 0.46" 0.638
MAR pm/day 0.15 0.34 0.18 0.44c
BFRJBS 0.15 0.46" 0.25 0.56"
pm3/pm2/
day
"P < 0.001; bp < 0.01; "P < 0.05
histology in both predialysis and maintenance dialysis patients. As
a result of the inclusion of these two patient populations, it was
possible to show that maintenance dialysis improves the bone
response to PTH.
The inclusion of an unselected group of dialysis patients should
be representative of our dialysis population. Forty-two percent of
j 40C
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Fig. 2. Intact PTH values in (A) predialysis, (B) hemodialysis, (C) CAPD, and CAPD + HD (D) patients according to the type of bone disease. A PTH value
< 120 pg/mI (lower dotted line) has a positive predictive value of 0.83 in predialysis patients and 0.89 in chronic dialysis patients for the diagnosis of
low turnover bone disease (aplastic or osteomalacia). Conversely, a PTH value > 450 pg/mI (upper dotted line) was 100% specific for the diagnosis of
hyperparathyroid bone disease (mild, osteitis fibrosa, mixed) in both predialysis and chronic dialysis patients. Abbreviations are: OM, osteomalacia; OF,
ostcitis fibrosa.
Table 5. Prediction of bone disease based on intact PTH cut-off
Positive
predictive
Sensitivity Specificity value
I. Low turnover bone disease
(aplastic and osteomalacia)
Cut-off: < 120 pg/mI
Predialysis 0.39 0.95 0.83
Dialysis 0.59 0.94 0.90
All 0.48 0.94 0.89
II. Non-low turnover disease (mild,
osteitis fibrosa, mixed)
Cut-off: > 450 pg/mI
Predialysis 0.53 1 1
Dialysis 0.50 1 1
All 0.43 1 1
the dialysis patients had aplastic bone disease; this bone lesion was
more frequent in CAPD than hemodialysis patients (48 vs. 32%).
These data are similar to the study recently reported by Sherrard
et a! [1]. In that study aplastic bone disease was present in 49% of
patients, and was also more common in CAPD (61%) than in
hemodialysis patients (36%). However, somewhat complicating
the interpretation of their data was the fact that 31% of their
patients with aplastic bone disease had a stainable bone surface
aluminum > 25% and another 30% had a stainable bone alumi-
num surface between 6 and 25% [1]. Thus, it could be argued that
aluminum exposure may have contributed to the development of
aplastic bone disease in this group of patients. Nevertheless, even
in the absence of significant bone aluminum staining our results
have established that aplastic bone disease has emerged as a
frequent finding in hemodialysis patients and is the most common
disorder in CAPD patients. Such a finding was rather uncommon
in previous reports of renal osteodystrophy [12, 19—22]. Of
additional interest was our observation that the incidence of
aplastic bone disease was similarly high (49%) in our predialysis
population. This result was somewhat higher than the 27%
recently reported by Hutchison et a! in a similar patient popula-
tion [5]. However, to our knowledge, the present study includes
for the first time, the simultaneous analysis of both predialysis and
dialysis populations from a single geographic area.
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Fig. 3. Relationship of osteoblast surface to plasma intact PTH levels in predialysis (A. y —0.38 + 0.005x; r = 0.88; P <0.001, N = 38), hemodialysis(B.y = —0.22 + 0.Olx; r 0.8/; N 49; P <0.01), CAPD (C.y = —0.42 + 0.09x; r 0.83; N 32; P <0.001 and CAPD + HD (D.y —0.34 +
0.Olx; r = 0.81; N = 81; P <0.001) patients. Mean regression line and 95% confidence limit bands are shown. The PTH range (95% confidence limit)
associated with an osteoblast surface of 1.5% (mean value of 18 normal individuals) is also shown in predialysis (A) and in chronic dialysis (D) patients.
Results of recent studies [1, 5] suggest that the incidence of
non-aluminum related aplastic bone disease has increased, but an
explanation is lacking. Possible considerations include the dialysis
of an increased number of diabetics and older individuals, de-
creased exposure to aluminum which results in less aluminum
bone disease, the more frequent use of calcium carbonate as a
phosphate binder, and the study of CAPD patients. In both
diabetics and older individuals, it is conceiveable that the ability to
develop marked parathyroid gland hyperplasia and the bone
response to PTH may be compromised. It is also possible that
aluminum exposure resulted in deposition of aluminum on the
bone surface in some patients that would have had low bone
turnover even in the absence of aluminum. Thus, aluminum could
have masked the diagnosis of idiopathic aplastic bone disease [231.
Common to CAPD and the increased use of calcium carbonate is
the effect that calcium loading may have had on the development
of aplastic bone disease. Finally, it should be added that care must
be taken to know the definition of aplastic bone disease when
different studies are compared. Sherrard et al [1, 13] and the
present study have used an osteoid volume < 15% as a diagnostic
criteria to separate osteomalacia and aplastic bone disease. How-
ever, the normal osteoid volume is < 5% and if this value is used
as the cut-off to separate aplastic bone disease from osteomalacia,
this could account for a lower incidence of aplastic bone disease
reported in the present and in other studies [1, 211.
As previously reported [7, 8, 241, we observed a significant
correlation between the PTH concentration and histologic param-
eters of bone activity. This correlation was not present with PTH
below 200 pglml or in patients with low bone turnover. It should
also be noted that the degree of corrrelation between PTH and
bone parameters may vary considerably depending on the types of
patients studied [7, 8]. For example, in the Cohen Solal et al study
[7], two-thirds of the patients had intact PTH values < 2 times the
upper limits of normal. As a result, the correlation between PTH
and bone histologic parameters was lower than in the study by
Quarles et a! [81 in which patients with low bone turnover were
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excluded; in that study, two-thirds of the patients had PTH values
more than four times the upper normal limit. The present study
clearly demonstrates that intact PTH levels correlate with both
static and dynamic parameters of bone histology. Furthermore,
our study indicates that a bias toward selection of patients with
low or high bone turnover could influence the results.
To our knowledge, a comparison of the relationship between
intact PTH and bone histologic parameters between predialysis
and dialysis patients has not been previously reported. In the
present study, the slope of the regression line between intact PTH
and different static (osteoblast surface, osteoclast number, and
marrow fibrosis) and dynamic (bone formation rate) bone param-
eters, was less steep in predialysis than in hemodialysis patients.
This result indicates that for a given PTFI value, the bone
response was greater in hemodialysis than in predialysis patients.
Although high phosphorus may affect the response of osteoblast—
like cells to PTH [25J, the finding of similar levels of phosphorus
in predialysis and hemodialysis patients (Table 1) suggests that
other factors contribute to the different bone response to PTH.
Patients on CAPD showed a similar slope of the intact PTH-
osteoblast surface regression line as patients on hemodialysis;
both regression lines were steeper than in predialysis patients.
Nevertheless, the slopes of the regression lines with other static
and dynamic bone parameters were similar in CAPD and predi-
alysis patients and less steep than in hemodialysis patients. This
different bone response to PTH in CAPD patients seems to be
related to a shorter duration of dialysis rather than to any effect of
dialysis modality per Se. As a matter of fact, when matching for
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Fig. 4. Relationship of volume of marrow fibrosis to plasma intact PTH levels in predialysis (A. y —0.32 + 0.003x; r = 0.74; P < 0.00]; N = 38),
hemodialysis (B.y = —0.72 + 0.007; r = 0.72; P <0.001; N = 49), CAPD (C.y = —0.07 + 0.002x; r = 0.65; P < 0.001; N = 32), and CAPD + HD(D.y = —0.63 + 0.006x; r = 0.68, P < 0.001; N = 81) patients. Mean regression line and 95% confidence limit bands are shown. The X-intercept of
the lower 95% confidence limit band is at 250 pg/mI in each group of patients.
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time on dialysis, hemodialysis and CAPD patients showed similar
slopes of the different regression lines.
Due to skeletal resistance to PTH, it may not be desirable to
decrease the PTH level to the normal range (10 to 65 pg/mI)
because this would likely result in low turnover bone disease.
Results from our study support this conclusion since an intact
PTH level below 120 pg/mi was highly predictive of low bone
turnover in both predialysis and dialysis patients (Fig. 2). More-
over, this value excluded the presence of advanced hyperparathy-
roid bone disease (osteitis fibrosa or mixed disease). This cut-off
levdl of PTH provided a positive predictive value of 83% and 90%
for the diagnosis of low turnover bone disease in predialysis and
dialysis patients, respectively. Only a limited number of patients
with mild hyperparathyroid bone disease had PTH levels < 120
pg/ml. Conversely, the presence of an intact PTH concentration
greater than 450 pg/ml excluded the diagnosis of low turnover
disease in both pre-dialysis and dialysis patients (Fig. 2). These
high values of intact PTH were associated with severe hyperpara-
thyroid bone disease (osteitis fibrosa or mixed disease) in 87% of
the patients. Similar observations have also been reported in
dialysis patients by Quarles et al [8].
To determine the PTH values associated with an optimal bone
histology we used the information derived from the correlations of
PTH with the different histomorphometric parameters. To main-
tain a normal osteoblast surface (1.5%) the intact PTH should
range between 75 to 260 pg/mI (95% confidence limit) in dialysis
patients (Fig. 3A). Moreover, when PTH levels were > 250 pg/ml
(959 confidence), marrow fibrosis developed in both hemodialy-
sis and CAPD patients (Fig. 4B-D). Thus, the optimal PTH range
to avoid both low turnover and hyperparathyroid bone disease in
dialysis patients appeared to be 120 to 250 pg/mI which is two to
four times the upper limit of normal PTH. These values are in the
same range as recommended by Quarles et al 181 for adults on
hemodialysis, and by Salusky et al (26) for pediatric patients on
CAPDICCPD. Similarly, this range of PTH would also result in
normal bone formation rates [14].
The PTH range required to maintain a normal osteoblast
surface in predialysis patients was 300 to 500 pg/ml (95% confi-
dence) (Fig. 3A). However, when PTH was> 250 pg/ml marrow
fibrosis became evident (Fig. 4A). If a marrow fibrosis < 0.5%
Fb.V/TV, the cut-off value of mild hyperparathyroid bone disease,
is acceptable, the PTH may be as high as 375 pg/ml (Fig. 4A).
Thus, in the predialysis patient, a PTH range between 300 and 375
pg/mi was necessary to achieve a normal osteoblast surface but
mild marrow fibrosis must be accepted.
In general, this analysis may not apply to patients receiving
calcitriol pulses to treat hyperparathyroidism. In dialysis patients
treated with intravenous calcitriol, the desired range of PTH may
be greater than 250 pg/ml. Preliminary results from two recent
studies have indicated that high doses of intravenous calcitriol
may have an independent suppressive effect on bone [27, 28] and
thus PTH levels in the 120 to 250 pg/mi range may not be optimal
for dialysis patients under such therapy. However, the possible
undesirable systemic effects of PTH on other organs need to be
evaluated.
In conclusion, aplastic bone disease without significant bone
surface aluminum was a common finding in our predialysis,
hemodialysis, and CAPD patients. Maintenance dialysis improved
the bone response to PTH. Finally, the results of our study help
define a range of intact PTH levels that would be desirable in
order to avoid both apiastic bone disease and significant hyper-
parathyroid bone disease.
Acknowledgments
This work was supported by FISS 92/0153 and CAICYT PB 85/0253
grants. The authors are grateful to Ms. Nuria Barros for technical
assistance.
Reprint requests to Dr. Armando Torres, Servicio de Nefrologla, Hospital
Universitario de Canarias, Ofra, La Laguna sn., 38320 Tenenfe, C'anaiy
Islands, Spain.
References
1. SHERRARD DJ, HERCZ U, PEI Y, MALONEY NA, GREENWOOD C,
MANUEL A, SHAIPn00 C, FENTON SS, SEGRE GV: The spectrum of
bone disease in end-stage renal failure: An evolving disorder. Kidney
Tnt 43:436—442, 1993
2. PEI Y, FIERCZ G, GREENWOOD C, SHERRARD D, SEGRE G, MANUEL A,
SHAIPHOO C, FENTON S: Non-invasive prediction of aluminum bone
disease in hemo and peritoneal dialysis patients. Kidney mt 41:1374—
1382, 1992
3. Pi Y, HERCZ G, GREENWOOD C, SEGRE 0, MANUEL A, SHAIPHOO C,
FENTON S, SHERRARD D: Renal osteodystrophy in diabetic patients.
Kidney mt 44:159—164, 1993
4. MALLUCHE HH, FAUGERE MC: Renal bone disease 1990: An unmet
challenge for the nephrologist. Kidney mt 38:193—211, 1990
5. HUTCHISON AJ, WHITEHOUSE RW, BOULTON HF, ADAMS JE, MAWER
EB, FREEMONT TJ, Goic.&i. R: Correlation of bone histology with
parathyroid hormone, vitamin D3, and radiology in end-stage renal
disease. Kidney mt 44:1071—1077, 1993
6. FELSENFELD AJ, RODRIGUEZ M, DUNLAY R, LLACH F: A comparison of
parathyroid gland function in haemodialysis patients with different forms
of renal osteödystrophy. Nephrol Dial Transplant 6:244—251, 1991
7. COHEN SOLAJ. ME, SEBERT JL, BOUDAILLIEZ B, MARIE A, MORINIERE
P, GUERIS J, BOUILLON R, FOURNIER A: Comparison of intact,
midregion, and carboxy terminal assays of parathyroid hormone for
the diagnosis of bone disease in hemodialyzed patients. J Clin
Endocrinol Metab 73:516—524, 1991
8. QU.Aiuus LID, LOBAUGFJ B, MURPHY G: Intact parathyroid hormone
overestimates the presence and severity of parathyroid-mediated osseous
abnormalities in uremia. J Cliii Endocrinol Metab 75:145—150, 1992
9. LORENZO V, TORRES A, GONZALEZ-POSADA JM, PESTANA M, Ro-
DR(GUZ A, DIAZ-FLORE5 L: Prevalencia de las distintas formas de
osteodistrofia renal, con especial referencia a Ia osteomalacia. Nefro-
logla 6:2—33, 1986
10. HERNANDEZ D, CONCEPCION MT, LORENZO V, MARTINEZ ME,
RODRIGUEZ A, Dn BODIS E, GONZALEZ-POSADA JM, FELSENFELD AJ,
RODRIGUEZ M, TORRES A: Non-aluminic aplastic bone disease in
predialysis patients: Prevalence and evolution after maintenance
dialysis. Nephrol Dial Transplant 9:517—523, 1994
11. MALONEY NA, O'vr SM, ALFREY AC, MILLER NL, COBURN JW,
SHERLkRD DJ: Histologic quantitation of aluminum in iliac bone from
patients with renal failure. J Lab Clin Med 99:202—21'6 1982
12. SHERRARD DJ, BAYLINK DJ, WERGEDAL JE, MALONEY N: Quantita-
tive histological studies on the pathogenesis of uremic bone disease. J
Clin Endocrinol Metab 39:119—135, 1974
13. SHERRARD DJ, Orr SM, MALONEY NA, ANDRESS D, COBURN JW:
Uremic osteodystrophy: Classification, cause and treatment, in Clini-
cal Disorders of Bone and Mineral Metabolism, edited by FRAME B,
Porrs JT JR, Amsterdam, Excerpta Medica, 1983, pp 254 —259
14. GARCIA CARRASCO M, GRUSON M, DE VERNEJOUL MC, DENNE MA,
MJRAVET L: Osteocalcin and bone morphometric parameters in adults
without bone disease. Calcif Tissue mt 42:13—17, 1988
15. MARASCUILO LA: Statistical Methods for Behavioural Science Re-
search. New York, McGraw-Hill, 1971, pp 497—508
16. GUJARATI D: Use of dummy variables in testing for equality between
sets of coefficients in linear regressions: A generalization. Am Statis-
tician 24:18—22, 1970
1442 Ton-es et al: Bone disease in predialysis and dialysis patients
17. Sox HC JR: Probability theoiy in the use of diagnostic tests. Ann mt
Med 104:60—66, 1986
18. Noiusis MJ: SPSS for Windows. SPSS Inc. Chicago, 1992
19. ANDRESS D, ENDRES D, MALONEY N, K0PP J, COBURN JW, SHERRARD
DJ: Comparison of parathyroid hormone assays with bone histomor-
phometry in renal osteodystrophy. J Clin Endocrinol Metab 63:1163—
1169, 1986
20. CHAzAN JA, LIBBEY NP, LONDON MR, PONO L, ABUELO JG: The
clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis
patients: A correlation between biochemical parameters and bone
pathology findings. Gun Nephrol 35:78—85, 1991
21. LLACH F, FELSENFELD AJ, COLEMAN M, KEVENEY J, PEDERSON J,
MEDLOCK R: The natural course of dialysis osteomalacia. Kidney mt
29:S74—S79, 1986
22. CHAN YK, FURLONG TJ, CORNIsH CJ, POSEN S: Dialysis osteodystro-
phy—A study involving 94 patients. Medicine 64:296—308, 1985
23. ANDRSS DL, Ko JB, MALONEY NA, COBURN JW, SFJERRARD JW
Early deposition of aluminum in bone in diabetic patients on hemo-
dialysis. N Engl J Med 316:292—296, 1987
24. MATHIAS R, SALUSKY I, HARMAN W, PAREDES A, EMANS J, SEGRE G,
GOODMAN W: Renal bone disease in pediatric and young adult
patients on hemodialysis in a children's hospital. JAm Soc Nephrol
3:1938—1946, 1993
25. GREEN J, KLEEMAN CR, SCHOTLAND S, CHAIMOVITZ C: Acute phos-
phate depletion dissociates hormonal stimulated second messengers
in osteoblast-like cells. Endocrinol 129:848—858, 1991
26. SALUSKY IB, RAMIREZ JA, OPPENHEIM W, GALES B, SEGRE GV,
GOODMAN WG: Biochemical markers of renal osteodystrophy in
pediatric patients undergoing CAPD/CCPD. Kidney mt 45:253—258,
1994
27. PAHI, J, BOVER J, JARA A, FELSENFELD A: Does calcitriol have a direct
effect on the bone independent of parathyroid hormone (PTH)?
(abstract) JAm Soc Nephrol 4:726, 1993
28. GOODMAN WG, RAMiREZ JA, BELIN T, GALES B, SEGRE GV, SALUSKY
IB: Adynamic bone after intermitent calcitriol therapy in pediatric
patients with secondary hyperparathyroidism. (abstract) J Am Soc
Nephrol 4:696, 1993
